Then they gradually increased to three/week
One regulatory note worth holding alongside his framing: the FDA placed several of the peptides he discusses (including BPC-157, CJC-1295, and Ipamorelin) onto a Category 2 list in 2023, citing a lack of safety data rather than reported harms
Czym jest BPC-157 sekwencja i klasa BPC-157 to syntetyczny pentadekapeptyd odpowiadajcy fragmentowi 15 aminokwasw ludzkiego biaka ochronnego odka

Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters

Compared with normal skin fibroblasts, a greater number of keloid fibroblasts displayed a senescent phenotype and were arrested at the G0/G1 phase using a serum-limited culture approach, indicating the senescent tendency of keloid fibroblasts under simulated ischemic stress